Physician profile
Uma Polam
NPI 1740241207
$1,661.79
in general payments reported to CMS, 2019-2025
27 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.28 · 2020: $36.63 · 2021: $73.87 · 2022: $123 · 2023: $317 · 2024: $405 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,364.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,363.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $479.88 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $210.42 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $200.18 | 2020-2025 | |
| Astellas Pharma US INC | $124.53 | 2024-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $76.59 | 2024-2025 | |
| Lilly USA, LLC | $60.25 | 2019-2024 | Zepbound, Mounjaro |
| Abbvie INC. | $53.38 | 2023 | |
| Merck Sharp & Dohme LLC | $37.09 | 2020-2021 | |
| Globus Medical, INC. | $36.96 | 2025 | Senza |
| Xeris Pharmaceuticals, INC. | $35.77 | 2025 | Gvoke Hypopen |
| Amarin Pharma, INC. | $29.82 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $27.76 | 2025 | Nuplazid |
| Dexcom, INC. | $27.29 | 2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.56 | 2025 | Jardiance |
| Azurity Pharmaceuticals, INC. | $23.66 | 2024 | Edarbi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $21.02 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $19.96 | 2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $18.89 | 2024 | |
| Allergan, INC. | $18.07 | 2019 | |
| Phadia US INC. | $17.77 | 2019 | |
| Seqirus USA INC | $17.50 | 2025 | Flucelvax, Fluad |
| Horizon Therapeutics Plc | $17.44 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.38 | 2025 | Eliquis |
| Hologic Sales and Service, LLC | $16.83 | 2025 | Aptima |
| Biohaven Pharmaceutical Holding Company Ltd. | $16.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.87 | 2024 | Voquezna |
| Janssen Pharmaceuticals, INC | $15.26 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Polam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.